Logo

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-394) Trial for the Treatment of Advanced HCC at ASCO GI 2022

Share this

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-394) Trial for the Treatment of Advanced HCC at ASCO GI 2022

Shots:

  • The P-III (KEYNOTE-394) trial evaluates Keytruda (IV, q3w, for 35 cycles) +BSC vs PBO + BSC in 453 patients in Asia with advanced HCC prior treated with sorafenib or oxaliplatin-based CT
  • The results showed an improvement in 1EPs of OS; 21% reduction in risk of death; m-OS (14.6mos. vs 13.0mos.); patients were alive @2yrs. (34.3% vs 24.9%) while an efficacy EPs showed a 26% reduction in risk of disease progression or death; m-PFS (2.6mos. vs 2.3mos.); ORR (12.7% vs 1.3%); m-DOR (23.9mos. vs 5.6mos.)
  • The therapy is being evaluated in multiple studies as monothx. & combination with other treatments. The company has a global development program of 7 trials & expects to enroll ~3,000 patients

Ref: Businesswire | Image: Merck 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions